Reserpine-induced Depletion of Neuropeptide Y from Cardiovascular Nerves and Adrenal Gland Due to Enhanced Release
Overview
Authors
Affiliations
The mechanisms underlying reserpine-induced depletion of neuropeptide Y-like immunoreactivity (NPY-LI) in relation to tissue content of noradrenaline (NA) and cardiovascular impairment were studied in guinea-pigs. Reserpine pretreatment (5 mg/kg SC) caused a 5-fold increase in plasma levels of NPY-LI with a maximum after 4 h. This was associated with a progressive fall in systemic arterial blood pressure and heart rate (to about 50% of basal values). The contents of NPY-LI and NA in nerves of the heart and quadriceps muscle were then reduced by about 75% and 85%, respectively. The adrenal content of NPY-LI was reduced by 40% 8 h after reserpine, while the adrenaline content was uninfluenced. Pretreatment with guanethidine depleted NA in the heart but did not influence plasma levels or tissue content of NPY-LI per se. The reserpine-induced increase in plasma NPY-LI and the depletion of NPY-LI in the heart and skeletal muscle was to a large extent prevented by guanethidine. The reserpine-induced bradycardia and hypotension were reduced after guanethidine pretreatment. Chlorisondamine pretreatment depressed heart rate, blood pressure and plasma levels of NPY-LI. Furthermore, chlorisondamine inhibited the reserpine-induced increase in plasma NPY-LI and prevented the reduction in tissue content of NPY-LI in the heart, skeletal muscle and adrenal.(ABSTRACT TRUNCATED AT 250 WORDS)
Reserpine-induced immunocytochemical change of neuropeptide Y in the hypothalamic arcuate nucleus.
Okamura H, Sugano T, Ibata Y Neurochem Res. 1996; 21(2):239-43.
PMID: 9182248 DOI: 10.1007/BF02529140.
Peptides in the mammalian cardiovascular system.
Wharton J, Gulbenkian S Experientia. 1987; 43(7):821-32.
PMID: 3297769 DOI: 10.1007/BF01945360.
Pernow J, Kahan T, Lundberg J Br J Pharmacol. 1988; 94(3):952-60.
PMID: 3179619 PMC: 1854060. DOI: 10.1111/j.1476-5381.1988.tb11609.x.
Evidence for co-transmitter role of neuropeptide Y in the pig spleen.
Lundberg J, Rudehill A, Sollevi A, Hamberger B Br J Pharmacol. 1989; 96(3):675-87.
PMID: 2566349 PMC: 1854405. DOI: 10.1111/j.1476-5381.1989.tb11868.x.
Higuchi H, Iwasa A, Miki N Br J Pharmacol. 1991; 103(1):1136-40.
PMID: 1878751 PMC: 1908071. DOI: 10.1111/j.1476-5381.1991.tb12313.x.